ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand
December 05 2019 - 5:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its
partnership with Matakana Health (MHL) until early 2023, which will
now include Australia in its territory. On Monday, ChromaDex
announced the receipt of approval of nicotinamide riboside chloride
(NR, or Niagen®) as an ingredient in listed Complementary Medicines
from the Australian Therapeutic Goods Administration (TGA).
MHL is an established dietary supplement
manufacturer and distributor in New Zealand with national and
Australian distribution in both online and offline channels. The
company has more than 90 lines of organic and superfood
products.
“Matakana successfully launched Tru Niagen® in
New Zealand in 2018,” says ChromaDex CEO Rob Fried. “We look
forward to building on that momentum together as we expand into
Australia.”
“We are excited to be expanding our relationship
with ChromaDex in Oceania. Tru Niagen has been taken up by New
Zealanders with great enthusiasm, and we expect to see the same
level of excitement and adoption of this groundbreaking product
from Australians in 2020,” says Matakana Health CEO Kevin
Glucina.
Tru Niagen is a breakthrough supplement proven
to increase your NAD (nicotinamide adenine dinucleotide) levels
which stimulate cellular energy production and support cellular
repair. Decreased NAD levels have been associated with many
age-related declines in overall health. NAD precursors such as
nicotinamide riboside (NR) have been the subject of rigorous
preclinical safety and toxicology studies laying the groundwork for
the published clinical studies that demonstrate safety and
efficacy.
NIAGEN® is the only commercially available NR
which has twice been successfully reviewed under U.S. Food &
Drug Association's (FDA) new dietary ingredient (NDI) notification
requirement and has also been successfully notified to the FDA as
generally recognized as safe (GRAS). In August, the European Food
Safety Authority (EFSA) issued a positive opinion on Nicotinamide
Riboside (NR) as a novel food ingredient for use in a food
supplement; in November, the European Commission voted in favor of
listing nicotinamide riboside chloride as a novel food.
For additional information on the science supporting Tru Niagen,
please visit www.truniagen.com.
For more information on Matakana Health and its products, visit
www.matakanasuperfoods.com.
About TRU NIAGEN®:
TRU NIAGEN® is a branded dietary supplement
brought to market by key nicotinamide riboside innovator and patent
holder, ChromaDex. NIAGEN® nicotinamide riboside (NR), also
supplied by ChromaDex, is the sole active ingredient in TRU
NIAGEN®. Multiple clinical trials demonstrate NIAGEN® is proven to
boost NAD (nicotinamide adenine dinucleotide) levels, which decline
with age. Only NIAGEN® has twice been successfully reviewed under
FDA's new dietary ingredient (“NDI”) notification program, and has
also been successfully notified to the FDA as generally recognized
as safe (“GRAS”).
About ChromaDex:
ChromaDex Corp. is a science-based integrated
nutraceutical company devoted to improving the way people age.
ChromaDex scientists partner with leading universities and research
institutions worldwide to uncover the full potential of NAD and
identify and develop novel, science-based ingredients. Its flagship
ingredient, NIAGEN® nicotinamide riboside, sold directly to
consumers as TRU NIAGEN®, is backed with clinical and scientific
research, as well as extensive IP protection. TRU NIAGEN® is
helping the world AGE BETTER®. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of
1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2018, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Media Contact:Alex Worsham, Senior
Director of Global Corporate Communications310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Vice President of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024